Abbott announces CE Mark for world’s longest coronary drug eluting stent
21 May 2013 | By Abbott
Abbott announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System...
List view / Grid view
21 May 2013 | By Abbott
Abbott announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary Stent System...
21 May 2013 | By Novartis
New global survey results...
20 May 2013 | By University of Cambridge
New research establishes nature of malfunction in protein molecules that can lead to onset of dementia...
20 May 2013 | By Elan Corporation
Elan Corporation announces a series of transactions designed to decisively transform and advance the company...
20 May 2013 | By FTI Consulting
Clinical and pre-clinical data highlighting the significant bronchodilator activity of novel dual PDE3/4 inhibitor RPL554...
17 May 2013 | By Novartis
Results of a pivotal Phase III trial...
17 May 2013 | By Novo Nordisk
Novo Nordisk announced the completion of paradigm™ 2...
17 May 2013 | By Novartis
"We are proud to be recognized by GBCHealth for our Arogya Parivar program..."
17 May 2013 | By Sanofi
The French ministerial mission has presented the conclusions of its report regarding the Sanofi Research site in Toulouse, France...
16 May 2013 | By UCB
UCB and IBM have announced the completion of the initial phase of a pioneering project...
16 May 2013 | By Biosector 2
Spinal Modulation Inc. designed the Axium™ Spinal Cord Stimulator System...
16 May 2013 | By Roche
First results from CLL11 announced...
16 May 2013 | By AstraZeneca
First patient enrolled in Phase III clinical trial...
16 May 2013 | By Biogen Idec
“Biogen Idec Foundation & East End House share an ongoing commitment..."
15 May 2013 | By Gilead Sciences
Gilead Sciences, Inc. announced results from a Phase 2 study...